XML 14 R48.htm IDEA: XBRL DOCUMENT v2.4.0.8
BUSINESS COMBINATIONS - Pro forma impact of business combinations (Details) (USD $)
In Millions, except Per Share data, unless otherwise specified
3 Months Ended 9 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Sep. 30, 2014
Sep. 30, 2013
Pro forma of consolidated results of operations        
Revenues $ 2,060.2 $ 1,867.3 $ 6,039.6 $ 5,794.9
Net income (loss) attributable to Valeant Pharmaceuticals International, Inc. $ 279.8 $ (907.8) $ 376.1 $ (1,023.9)
Earnings (loss) per share attributable to Valeant Pharmaceuticals International, Inc.:        
Basic (in dollars per share) $ 0.83 $ (2.72) $ 1.12 $ (3.07)
Diluted (in dollars per share) $ 0.82 $ (2.72) $ 1.10 $ (3.07)